$KURA

471,993 Shares in Kura Oncology, Inc. $KURA Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC opened a new position in Kura Oncology, Inc. (NASDAQ:KURA) in Q4, buying 471,993 shares valued at about $4.9 million, according to Holdings Channel. Other funds also increased stakes, including Jacobs Levy, Qube Research, Nan Fung Trinity, UBS Group and Man Group. KURA last reported EPS of -$0.83 on $18.27 million revenue (vs. $25.97 million consensus).

Original reporting
Published May 29, 2026, 9:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 9:52 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
471,993 Shares in Kura Oncology, Inc. $KURA Acquired by Fisher Asset Management LLC — source image
Decision brief

The 30-second read

$KURABullishLow
01

Why it matters

The only fresh, tradable element is the reported new position and additional stake increases by several funds; it may influence sentiment but lacks a direct fundamental trigger.

02

Market read

Use as a sentiment/flow input rather than a standalone catalyst; monitor whether institutional accumulation coincides with upcoming clinical or earnings milestones.

03

What to watch

The article also notes weaker revenue vs consensus in the last reported quarter; without new clinical data, the ownership signal may fade.

Relevance 6/10Novelty 4/10Timing: today’s pre-/early-session positioning based on reported institutional buys

Background

The piece summarizes institutional ownership changes (13F/holdings channel) and reiterates recent trading/financial stats and analyst rating/target context.

Company-level read

Ticker impact

$KURABullishMedium confidence
Context

Fisher Asset Management LLC initiated a new position in Kura Oncology, buying 471,993 shares worth about $4.9M per the article.

Expected impact

Near-term support possible if flows persist; otherwise limited impact versus upcoming clinical/earnings catalysts.

Evidence & confidence

The article is a 13F/holdings-style ownership update (position size and valuation) without any company-specific operational news.

Market effects

Adds incremental sentiment to small/mid-cap clinical-stage biotech, but does not change sector fundamentals.

Primarily US biotech sentiment; no regional macro/regulatory trigger cited.

Limited global relevance; ownership changes are company-specific and not tied to international events.

Counterpoint

Institutional 13F-style buying can lag fundamentals and may reflect portfolio rebalancing rather than a new conviction catalyst.

Key entities

  • Kura Oncology, Inc.

    Clinical-stage biopharmaceutical company; subject of the institutional ownership update in the article.

  • Fisher Asset Management LLC

    Reportedly bought a new position in Kura Oncology (471,993 shares).

Related articles

$KURAMedAI 9/10

Kura Oncology Touts KOMZIFTI Launch Momentum, $3B Frontline AML Opportunity

Kura Oncology (NASDAQ:KURA) said at TD Cowen’s Oncology Innovation Summit it is building momentum for its newly approved AML therapy KOMZIFTI (ziftomenib) in relapsed/refractory NPM1-mutant AML, citing 85 new patient starts and 157 prescriptions in Q1 and $5.8M revenue. Executives also highlighted darlifarnib+adagrasib solid-tumor response data and updated KOMET-007 results ahead of ASCO and EHA.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.